Accelmed expands its leadership team

The leadership expansion comes after Accelmed's 2nd fund closed at its hard cap of $400 million earlier this year, and amid recent investments in TearLab, NeuroPace (which recently went public) and MedMinder.

DealsHealthcareBriefs